MEPs back plans for EMA relocation to Amsterdam but set conditions

16 March 2018
ema_big

Members of the European Parliament (MEPs) on Thursday voted in favor of enacting the law for the European Medicines Agency’s relocation from London to Amsterdam, Netherlands, due to Brexit,

However, they criticised the fact that "such an important decision" was taken by drawing lots. Italy, which just missed out in the ballot, has launched a legal bid to overturn the choice of Amsterdam after it emerged the Dutch facility would not be ready on time.

MEPs nonetheless pressed the EU Commission and the Dutch authorities to deliver the new facilities on time, so as to ensure a smooth transition for the Agency and let it move to its temporary location no later than January 1, 2019 and to its new permanent headquarters no later than November 16,  2019. This means that the EMA will initially relocate to temporary accommodation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical